Aquestive Therapeutics, Inc. AQST Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$83.78M-89.8% | -$44.14M-461% | -$7.87M+85.5% | -$54.41M+22.9% | ||
| $548K-23.7% | $718K-46.6% | $1.35M-43.7% | $2.39M-19.5% | ||
| $7.62M+7.4% | $7.1M+164% | $2.69M-38.6% | $4.38M-35.8% | ||
| -$52.43M-46.6% | -$35.76M-460% | -$6.38M— | —— | ||
| $562K+253% | $159K-84.0% | $995K-2.8% | $1.02M+12.2% | ||
| -$562K-253% | -$159K+84.0% | -$995K+60.6% | -$2.52M-176% | ||
| —— | $23K— | —— | —— | ||
| $102.72M+22.9% | $83.61M+2,004% | $3.97M-66.1% | $11.73M-61.0% | ||
| —— | —— | —— | —— | ||
| -$52.99M-47.5% | -$35.92M-387% | -$7.38M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aquestive Therapeutics, Inc. generate?
- Aquestive Therapeutics, Inc. (AQST) generated -$43.8M in operating cash flow over the trailing twelve months.
- What is Aquestive Therapeutics, Inc.'s free cash flow?
- After $479.0K of capital expenditures, Aquestive Therapeutics, Inc.'s free cash flow was -$44.3M over the trailing twelve months, up 9.6% year over year.
- Where does Aquestive Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
